LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ: OCUL) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Ocular investigation page on our website at www.glancylaw.com/case/ocular-therapeutix-inc.
On May 5, 2017, the Company disclosed that it received a Form 483 from the FDA containing “inspectional observations” related to the Company’s manufacturing and analytical testing procedures.
Then, on July 6, 2017, a report was published on SeekingAlpha.com alleging that management had been misleading investors regarding the severity of the Company’s manufacturing troubles. On this news, the Company’s share price fell more than 22% during intraday trading on July 7, 2017, thereby injuring investors.
If you purchased Ocular securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.